Phase I start brings ChemoCentryx $10 million GSK milestone
This article was originally published in Scrip
Executive Summary
ChemoCentryx has secured a $10 million milestone payment from GlaxoSmithKline by launching a Phase I trial with CCX832, the fourth and final drug candidate discovered and developed by the US company under its August 2006 strategic alliance with GSK. With the discovery phase of the alliance now concluded, ChemoCentryx is stepping up its efforts on other drug development programmes.